Sativex
From Glioblastoma Treatments
| Property | Information |
|---|---|
| Drug Name | Sativex (Nabiximols) |
| FDA Approval | Not FDA-approved in the United States; approved in several countries for spasticity due to multiple sclerosis |
| Used for | Investigational use in glioblastoma for potential direct anti-tumor effects and symptom management |
| Clinical Trial Phase | Phase 2 clinical trial in 2021 indicated for glioblastoma |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Fatigue, dizziness, nausea, mouth irritation |
| OS without | Not specified |
| OS with | The 2021 trial reported an increase in overall survival for glioblastoma patients treated with Sativex in combination with temozolomide compared to temozolomide alone |
| PFS without | Not specified |
| PFS with | Details on progression-free survival (PFS) improvement need further clarification; the trial primarily highlighted improvements in overall survival |
| Usefulness Rating | 4 |
| Usefulness Explanation | Not specified |
| Toxicity Level | Not specified |
| Toxicity Explanation | Not specified |
Notes: In a notable 2021 trial, Sativex, combined with temozolomide, demonstrated an increase in overall survival among glioblastoma patients, marking a promising advancement in the use of cannabinoid-based therapies for cancer treatment. These results suggest Sativex may possess anti-tumor properties in addition to its symptom management potential, warranting further research to fully understand its therapeutic benefits and mechanism of action in glioblastoma.
From Ben Williams Book: Not specified
Loading comments...
